With regard to our manuscripts on the commercial saliva substitute, Oralbalance®--its formula has been changed by Sugiura, Yuko et al.
Letter to the editor 
 
With regard to our manuscripts on the commercial saliva substitute, 
Oralbalance®—its formula has been changed 
 
Yuko Sugiura1*, Yoshihiko Soga2*, Ichiro Tanimoto3, Susumu Kokeguchi4, Sachiko 
Morishige-Nishide5**, Kotoe Itami-Kono6**, Kanayo Takahashi7, Nobuharu Fujii8, 
Fumihiko Ishimaru9**, Mitsune Tanimoto8, Kokoro Yamabe10*, Soichiro Tsutani11*, 
Fusanori Nishimura12*, Shogo Takashiba3 
 
1. Division of Dental Hygienist, Clinical Support Department, Okayama 
University Hospital, Okayama, Japan 
2. Division of Hospital Dentistry, Central Clinical Department, Okayama 
University Hospital, Okayama, Japan 
3. Department of Patho-physiology - Periodontal Science, Okayama University 
Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 
Okayama, Japan 
*Former address (belonged when previous studies were performed) 
4. Department of Global Health and Environmental Sciences - Oral Microbiology, 
Okayama University Graduate School of Medicine, Dentistry and 
Pharmaceutical Sciences, Okayama, Japan 
5. Department of Nursing, Kagawa University Hospital, Kagawa, Japan 
6. Department of Nursing, Sanyo Gakuen University, Okayama, Japan 
7. Department of Nursing, Okayama University Hospital, Okayama, Japan 
 ** Former address (belonged when previous studies were performed) 
8.  Department of Hematology, Oncology and Respiratory Medicine, Okayama 
University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama, Japan 
  *** Former address (belonged when previous studies were performed) 
9.  Japanese Red Cross Tokyo Metropolitan Blood Center, Tokyo, Japan 
10. Department of Dentistry, Rakuwakai Otowa Hospital, Kyoto, Japan 
11. Private clinic 
12. Department of Periodontology, Division of Oral Rehabilitation, Faculty of 
Dental Science, Kyushu University 
 
 
Corresponding author: 
Shogo Takashiba, D.D.S., Ph.D. 
Professor and Chair 
Department of Patho-physiology - Periodontal Science 
Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences 
2-5-1 Shikata-cho, Okayama 700-8525, Japan 
Tel: 81-86-235-6675 Fax: 81-86-235-6679 
e-mail: stakashi@cc.okayama-u.ac.jp 
 
To the editor, 
 
Previously, we published two articles in Supportive Care in Cancer on the in vitro and 
in vivo antibacterial effects of a commercial saliva substitute, Oralbalance® (Laclede, 
Inc., Rancho Dominguez, CA, USA; now GlaxoSmithKline, UK), which was a historic 
product for over 20 years and contributed to oral management for cancer patients with 
side effects such as xerostomia. The first report was entitled “Antimicrobial effects of 
the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the 
hematopoietic cell transplantation period” (Sugiura Y et al., Support Care Cancer, 2008 
[2]), and the other was “Total bacterial counts on oral mucosa after using a commercial 
saliva substitute in patients undergoing hematopoietic cell transplantation” (Sugiura Y et 
al., Support Care Cancer, 2010 [3]). Recently, however, the formula for this product has 
been changed. Antimicrobial enzymes have been removed, and our previous reports are 
no longer relevant. We would like to avoid reader misunderstanding related to our 
articles. 
High-dose chemotherapy and total-body irradiation, which are performed as the 
conditioning regimen for hematopoietic cell transplantation (HCT), are associated with 
xerostomia. Oralbalance® has been reported to alleviate the symptoms of 
post-radiotherapy xerostomia in head and neck cancer patients [1, 4]. Therefore, we 
postulated that this product may be effective in HCT patients. Based on our in vitro 
results, we concluded that Oralbalance® does not facilitate increases in microorganisms 
in the HCT period. Oral care with Oralbalance does not promote infection in patients 
undergoing HCT [2]. From our in vivo results, in neutropenic patients undergoing HCT, 
Oralbalance® did not increase the total counts of oral mucosal bacteria beyond the 
range found in healthy controls. Oral care using Oralbalance® may alleviate the 
symptoms induced by hyposalivation without promoting infection [3]. These 
antibacterial results were related to the enzymes present in the formulation. In our 
previous in vitro study, we demonstrated that the antibacterial effects of Oralbalance® 
were mainly due to antimicrobial enzymes of salivary origin, i.e., lactoperoxidase, 
lysozyme, and lactoferrin. However, these antibacterial enzymes have been removed 
with the recent formula change, and the product is now composed of glycerin, water, 
sorbitol, xylitol, carbomer, hydroxyethyl cellulose, sodium hydroxide, and 
propylparaben (cited from http://www.biotene.com/products/gel, accessed on 13 June 
2014) with no enzymes. Therefore, we cannot guarantee our results with the new 
formula, despite its use of the same name. Further studies on the product with the new 
formula are required. 
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